文献速递治疗药物监测与药物基因组学

CYP2D6基因多态性与利培酮药代动力学:系统评价与荟萃分析

CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis.
PubMed 文献 · Pharmacotherapy · 2020-07-12

该系统评价与荟萃分析纳入15项研究共2125名成人,采用标准化基因型-表型转换评估CYP2D6功能对利培酮暴露的影响,发现多剂量口服下CYP2D6中间代谢者和慢代谢者的利培酮剂量调整稳态浓度分别较正常代谢者高2.35倍和6.20倍,活性部分分别高1.18倍和1.44倍。

要点

  • CYP2D6中间代谢者利培酮稳态浓度较正常代谢者高2.35倍。
  • CYP2D6慢代谢者利培酮稳态浓度较正常代谢者高6.20倍。
  • 活性部分浓度升高幅度小于利培酮原药。

核心结论

  • 遗传决定的CYP2D6功能受损与口服利培酮成人中利培酮及活性部分暴露增加相关。

研究设计与样本

  • 系统评价与荟萃分析纳入15项研究共2125名成人受试者,采用标准化基因型-表型转换方法分组。

主要发现

  • 多剂量口服下,CYP2D6中间代谢者利培酮剂量调整稳态血清/血浆浓度较正常代谢者高2.35倍(95%CI 1.77-3.13,p<0.0001)。
  • 多剂量口服下,CYP2D6慢代谢者利培酮剂量调整稳态浓度较正常代谢者高6.20倍(95%CI 5.05-7.62,p<0.0001)。
  • 多剂量口服下,CYP2D6中间代谢者活性部分剂量调整稳态浓度较正常代谢者高1.18倍(95%CI 1.11-1.25,p<0.0001)。
  • 多剂量口服下,CYP2D6慢代谢者活性部分剂量调整稳态浓度较正常代谢者高1.44倍(95%CI 1.23-1.69,p<0.0001)。
  • 单剂量研究中也发现利培酮及活性部分AUC升高。

临床怎么用

  • 对口服利培酮的成人,可考虑CYP2D6基因型指导剂量调整,尤其慢代谢者需警惕暴露显著升高。

局限性

  • 需进一步研究量化这些药代动力学差异的临床影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Risperidone is a second-generation antipsychotic drug metabolized to an active metabolite, 9-hydroxyrisperidone, primarily by cytochrome P450 (CYP) 2D6 and to a lesser extent by CYP3A4. The extent to which drug metabolism genetics impacts risperidone and 9-hydroxyrisperidone exposure has not been clarified. OBJECTIVE: A systematic review and meta-analysis evaluated the impact of genetically defined CYP2D6 function on risperidone pharmacokinetics applying a standardized genotype-phenotype translation system. METHODS: A comprehensive electronic database search identified studies reporting relationships between genetically determined CYP2D6 metabolism and risperidone pharmacokinetic properties. The exposure of risperidone or active moiety (risperidone + 9-hydroxyrisperidone) was measured by dose-adjusted steady-state serum or plasma concentration or area under the concentration-time curve as primary outcomes. Subjects were assigned to CYP2D6 poor metabolizer, intermediate metabolizer, normal metabolizer, or ultrarapid metabolizer groups using a standardized genotype-phenotype translation method. Effect sizes between groups were pooled and stratified by single or multiple dosing regimens. RESULTS: A total of 15 studies involving 2125 adult subjects were included in the meta-analysis. Following multiple-dose oral administration, compared with CYP2D6 normal metabolizers, the risperidone dose-adjusted steady-state serum/plasma concentration was 2.35-fold higher in intermediate metabolizers (95% confidence interval [CI] 1.77-3.13, p<0.0001) and 6.20-fold higher in poor metabolizers (95% CI 5.05-7.62, p<0.0001); the active moiety dose-adjusted steady-state concentration was 1.18-fold higher in intermediate metabolizers (95% CI 1.11-1.25, p<0.0001) and 1.44-fold higher in poor metabolizers (95% CI 1.23-1.69, p<0.0001). Higher area under the concentration-time curve of risperidone and active moiety was also found in single-dose studies. CONCLUSION: Genetically defined impaired CYP2D6 activity is associated with increased exposure of both risperidone and risperidone + 9-hydroxyrisperidone in adults receiving oral formulations. Additional studies are needed to quantify the clinical impact of these relationships.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

引用

  1. Zhang L, Brown SJ, Shan Y, et al. CYP2D6 Genetic Polymorphisms and Risperidone Pharmacokinetics: A Systematic Review and Meta-analysis. Pharmacotherapy. 2020. PMID: 32519344. doi:10.1002/phar.2434

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。